uniQure (NASDAQ:QURE) Trading 6.7% Higher – Here’s Why

uniQure (NASDAQ:QURE)’s stock price traded up 6.7% during trading on Friday . The company traded as high as $12.82 and last traded at $12.88. 457,312 shares were traded during mid-day trading, a decline of 54% from the average session volume of 1,003,241 shares. The stock had previously closed at $12.07.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Cantor Fitzgerald boosted their target price on uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 10th. Raymond James raised uniQure from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the stock from $20.00 to $52.00 in a research note on Tuesday, December 10th. The Goldman Sachs Group boosted their price objective on uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research note on Thursday, December 12th. Royal Bank of Canada reissued an “outperform” rating and set a $24.00 price objective on shares of uniQure in a research note on Tuesday, January 21st. Finally, Wells Fargo & Company reduced their price objective on uniQure from $35.00 to $30.00 and set an “equal weight” rating on the stock in a research note on Friday. One analyst has rated the stock with a sell rating, three have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, uniQure presently has a consensus rating of “Moderate Buy” and an average target price of $38.89.

uniQure Stock Performance

The stock has a market cap of $640.73 million, a P/E ratio of -2.65 and a beta of 0.38. The business has a 50 day moving average price of $15.05 and a 200 day moving average price of $9.81. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92.

Insider Activity

In related news, CEO Matthew C. Kapusta sold 6,717 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $11.32, for a total value of $76,036.44. Following the completion of the sale, the chief executive officer now owns 580,795 shares in the company, valued at approximately $6,574,599.40. The trade was a 1.14 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Christian Klemt sold 2,916 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total value of $33,009.12. Following the completion of the sale, the chief financial officer now owns 155,168 shares of the company’s stock, valued at $1,756,501.76. The trade was a 1.84 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 55,915 shares of company stock valued at $588,112. 4.74% of the stock is currently owned by insiders.

Institutional Trading of uniQure

A number of large investors have recently modified their holdings of QURE. Assenagon Asset Management S.A. boosted its holdings in shares of uniQure by 49.1% in the third quarter. Assenagon Asset Management S.A. now owns 271,346 shares of the biotechnology company’s stock valued at $1,338,000 after purchasing an additional 89,400 shares during the period. abrdn plc boosted its holdings in shares of uniQure by 381.7% in the third quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock valued at $9,510,000 after purchasing an additional 1,528,581 shares during the period. Atria Investments Inc purchased a new stake in uniQure during the third quarter worth $53,000. Privium Fund Management B.V. lifted its holdings in uniQure by 16.3% during the third quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock worth $3,672,000 after buying an additional 104,500 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in uniQure during the third quarter worth $69,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.